{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:13:28Z","timestamp":1742444008530,"version":"3.40.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04119-9","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:00:09Z","timestamp":1742385609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and experimental aspects of tirbanibulin treatments"],"prefix":"10.1007","volume":"317","author":[{"given":"Annabel","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A.","family":"Simonette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Rady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"4119_CR1","doi-asserted-by":"publisher","unstructured":"Werner RN, Sammain A, Erdmann R, Hartmann V et al (2013) The natural history of actinic keratosis: a systematic review. Br J Dermatol. 169(3):502\u2013\u200918. https:\/\/doi.org\/10.1111\/bjd.12420. PMID: 23647091","DOI":"10.1111\/bjd.12420"},{"key":"4119_CR2","doi-asserted-by":"publisher","unstructured":"Glogau RG (2000) The risk of progression to invasive disease. J Am Acad Dermatol. 42(1 Pt 2):23\u2013\u20094. https:\/\/doi.org\/10.1067\/mjd.2000.103339. PMID: 10607353","DOI":"10.1067\/mjd.2000.103339"},{"issue":"2","key":"4119_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1524-4725.1995.tb00141.x","volume":"21","author":"RM Hurwitz","year":"1995","unstructured":"Hurwitz RM, Monger LE (1995) Solar keratosis: an evolving squamous cell carcinoma. Dermatol Surg 21(2):184. https:\/\/doi.org\/10.1111\/j.1524-4725.1995.tb00141.x","journal-title":"Dermatol Surg"},{"key":"4119_CR4","doi-asserted-by":"publisher","unstructured":"Padilla RS, Sebastian S, Jiang Z, Nindl I, Larson R (2010) Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma. Arch Dermatol. 146(3):288\u2013\u200993. https:\/\/doi.org\/10.1001\/archdermatol.2009.378. PMID: 20231500","DOI":"10.1001\/archdermatol.2009.378"},{"key":"4119_CR5","doi-asserted-by":"publisher","unstructured":"Hufbauer M, Akg\u00fcl B (2017) Molecular Mechanisms of Human Papillomavirus Induced Skin Carcinogenesis. Viruses. 9(7):187. https:\/\/doi.org\/10.3390\/v9070187. PMID: 28708084","DOI":"10.3390\/v9070187"},{"issue":"1\u20132","key":"4119_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.virol.2013.04.017","volume":"445","author":"W Joshua","year":"2013","unstructured":"Joshua W, Wang, Richard BS, Roden (2013) L2, the minor capsid protein of papillomavirus. Virology 445(1\u20132):175\u2013186. https:\/\/doi.org\/10.1016\/j.virol.2013.04.017","journal-title":"Virology"},{"key":"4119_CR7","doi-asserted-by":"publisher","first-page":"100196","DOI":"10.1016\/j.pvr.2020.100196","volume":"9","author":"L Galati","year":"2020","unstructured":"Galati L, Brancaccio RN, Robitaille A et al (2020) Detection of human papillomaviruses in paired healthy skin and actinic keratosis by next generation sequencing. Papillomavirus Res 9:100196. https:\/\/doi.org\/10.1016\/j.pvr.2020.100196PMID: 32222599; PMCID: PMC7118314","journal-title":"Papillomavirus Res"},{"key":"4119_CR8","doi-asserted-by":"publisher","unstructured":"Weissenborn SJ, Nindl I, Purdie K et al (2005) Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol. 125(1):93\u2013\u20097. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23733.x. PMID: 15982308","DOI":"10.1111\/j.0022-202X.2005.23733.x"},{"key":"4119_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3389\/fonc.2019.00355","volume":"9","author":"T Gheit","year":"2019","unstructured":"Gheit T (2019) Mucosal and cutaneous human papillomavirus infections and Cancer biology. Front Oncol 9:355. https:\/\/doi.org\/10.3389\/fonc.2019.00355PMID: 31134154; PMCID: PMC6517478","journal-title":"Front Oncol"},{"issue":"2","key":"4119_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/v13020321","volume":"13","author":"AN Della Fera","year":"2021","unstructured":"Della Fera AN, Warburton A, Coursey TL, Khurana S, McBride AA (2021) Persistent human papillomavirus infection. Viruses 13(2):321. https:\/\/doi.org\/10.3390\/v13020321PMID: 33672465; PMCID: PMC7923415","journal-title":"Viruses"},{"key":"4119_CR11","doi-asserted-by":"publisher","unstructured":"de Jong Sarah J, Imahorn Elias I, Peter et al (2018) Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human Beta-Papillomaviruses. Front Microbiol. 9:1222. https:\/\/doi.org\/10.3389\/fmicb.2018.01222","DOI":"10.3389\/fmicb.2018.01222"},{"key":"4119_CR12","doi-asserted-by":"publisher","unstructured":"Smola S (2020) Human Papillomaviruses and Skin Cancer. Adv Exp Med Biol. 1268:195\u2013209. https:\/\/doi.org\/10.1007\/978-3-030-46227-7_10. PMID: 32918220","DOI":"10.1007\/978-3-030-46227-7_10"},{"key":"4119_CR13","doi-asserted-by":"publisher","first-page":"20180287","DOI":"10.1098\/rstb.2018.0287","volume":"374","author":"A Venuti","year":"2019","unstructured":"Venuti A, Lohse S, Tommasino M, Smola S (2019) Cross-talk of cutaneous beta human papillomaviruses and the immune system. Phil Trans R Soc B 374:20180287. https:\/\/doi.org\/10.1098\/rstb.2018.0287","journal-title":"Phil Trans R Soc B"},{"issue":"3","key":"4119_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1468-2494.2010.00616.x","volume":"33","author":"JM Gillbro","year":"2011","unstructured":"Gillbro JM, Olsson MJ (2011) The melanogenesis and mechanisms of skin-lightening agents\u2013existing and new approaches. Int J Cosmet Sci 33(3):210\u2013221. https:\/\/doi.org\/10.1111\/j.1468-2494.2010.00616.xEpub 2011 Jan 25. PMID: 21265866","journal-title":"Int J Cosmet Sci"},{"key":"4119_CR15","doi-asserted-by":"publisher","unstructured":"Tomai\u0107 V (2016) Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies. Cancers (Basel). 8(10):95. https:\/\/doi.org\/10.3390\/cancers8100095. PMID: 27775564","DOI":"10.3390\/cancers8100095"},{"key":"4119_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jdv.14152","volume":"31","author":"G Goldenberg","year":"2017","unstructured":"Goldenberg G (2017) Treatment considerations in actinic keratosis. J Eur Acad Dermatol Venereol 31:12\u201316. https:\/\/doi.org\/10.1111\/jdv.14152","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"4119_CR17","first-page":"741","volume":"13","author":"B Berman","year":"2014","unstructured":"Berman B, Goldenberg G, Hanke CW, Tyring SK, Werschler WP, Knudsen KM, Larsson T, Swanson N (2014) Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol 13(6):741\u2013747 PMID: 24918567","journal-title":"J Drugs Dermatol"},{"key":"4119_CR18","doi-asserted-by":"publisher","unstructured":"Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF (2004) Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 140(7):813-6. https:\/\/doi.org\/10.1001\/archderm.140.7.813. PMID: 15262691","DOI":"10.1001\/archderm.140.7.813"},{"key":"4119_CR19","unstructured":"McDaniel B, Badri T, Steele RB Basal Cell Carcinoma. [Updated 2024 Mar 13]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482439\/"},{"issue":"8","key":"4119_CR20","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-18-1122","volume":"25","author":"MM Priyadharsini Nagarajan","year":"2019","unstructured":"Priyadharsini Nagarajan MM, Asgari AC, Green et al (2019) Keratinocyte carcinomas: current concepts and future research priorities. Clin Cancer Res 25(8):2379\u20132391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1122","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4119_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0190-9622(84)80334-5","volume":"10","author":"Hv Domarus","year":"1984","unstructured":"Domarus Hv, Peter J, Stevens (1984) Metastatic basal cell carcinoma: report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 10(6):1043\u20131060. https:\/\/doi.org\/10.1016\/S0190-9622(84)80334-5","journal-title":"J Am Acad Dermatol"},{"key":"4119_CR22","doi-asserted-by":"publisher","unstructured":"Mukovozov I, Roesler J, Kashetsky N, Gregory A (2023) Treatment of Lentigines: A Systematic Review. Dermatol Surg. 49(1):17\u201324. https:\/\/doi.org\/10.1097\/DSS.0000000000003630. PMID: 36533790","DOI":"10.1097\/DSS.0000000000003630"},{"issue":"9","key":"4119_CR23","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.3390\/ijms10094066","volume":"10","author":"JP Ebanks","year":"2009","unstructured":"Ebanks JP, Wickett RR, Boissy RE (2009) Mechanisms regulating skin pigmentation: the rise and fall of complexion coloration. Int J Mol Sci 10(9):4066\u20134087. https:\/\/doi.org\/10.3390\/ijms10094066PMID: 19865532; PMCID: PMC2769151","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4119_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13555-024-01310-0","volume":"15","author":"F Li Pomi","year":"2025","unstructured":"Li Pomi F, d\u2019Aloja A, Rottura M, Vaccaro M, Borgia F (2025) The Skin-Lightening power of Tirbanibulin 1% ointment. Dermatol Ther (Heidelb) 15(1):95\u2013110. https:\/\/doi.org\/10.1007\/s13555-024-01310-0Epub 2024 Nov 30. PMID: 39614963; PMCID: PMC11785872","journal-title":"Dermatol Ther (Heidelb)"},{"key":"4119_CR25","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.2147\/CCID.S479411","volume":"17","author":"T Chen","year":"2024","unstructured":"Chen T, Xue J, Wang Q (2024) Tranexamic acid for the treatment of hyperpigmentation and telangiectatic disorders other than melasma: an update. Clin Cosmet Investig Dermatol 17:2151\u20132163. https:\/\/doi.org\/10.2147\/CCID.S479411PMID: 39350932; PMCID: PMC11439988","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"4119_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/ijd.16160","volume":"62","author":"KM Kim","year":"2023","unstructured":"Kim KM, Lim HW (2023) The uses of Tranexamic acid in dermatology: a review. Int J Dermatol 62(5):589\u2013598. https:\/\/doi.org\/10.1111\/ijd.16160Epub 2022 Mar 24. PMID: 35323992","journal-title":"Int J Dermatol"},{"issue":"7","key":"4119_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00403-024-03032-x","volume":"316","author":"VK DeTemple","year":"2024","unstructured":"DeTemple VK, Walter A, Bredemeier S, Gutzmer R, Schaper-Gerhardt K (2024) Anti-tumor effects of Tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization. Arch Dermatol Res 316(7):341. https:\/\/doi.org\/10.1007\/s00403-024-03032-xPMID: 38847867; PMCID: PMC11161541","journal-title":"Arch Dermatol Res"},{"key":"4119_CR28","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.2147\/CCID.S374122","volume":"15","author":"T Schlesinger","year":"2022","unstructured":"Schlesinger T, Stockfleth E, Grada A, Berman B (2022) Tirbanibulin for actinic keratosis: insights into the mechanism of action. Clin Cosmet Investig Dermatol 15:2495\u20132506. https:\/\/doi.org\/10.2147\/CCID.S374122","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"4119_CR29","doi-asserted-by":"publisher","unstructured":"Gilaberte Y, Fern\u00e1ndez-Figueras MT (2022) Tirbanibulin: review of its novel mechanism of action and how it fits into the treatment of actinic keratosis. Actas Dermosifiliogr. 113(1):58\u201366. https:\/\/doi.org\/10.1016\/j.ad.2021.07.006. PMID: 35249711","DOI":"10.1016\/j.ad.2021.07.006"},{"issue":"48","key":"4119_CR30","doi-asserted-by":"publisher","first-page":"18099","DOI":"10.1074\/jbc.RA119.010732","volume":"294","author":"L Niu","year":"2019","unstructured":"Niu L, Yang J, Yan W et al (2019) Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of \u03b2-tubulin explains KXO1\u2019s low clinical toxicity. J Biol Chem 294(48):18099\u201318108. https:\/\/doi.org\/10.1074\/jbc.RA119.010732PMID: 31628188; PMCID: PMC6885616","journal-title":"J Biol Chem"},{"issue":"11","key":"4119_CR31","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1021\/acs.jmedchem.8b00164","volume":"61","author":"MP Smolinski","year":"2018","unstructured":"Smolinski MP, Bu Y, Clements J et al (2018) Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2-391 and KX2-361). J Med Chem 61(11):4704\u20134719. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00164","journal-title":"J Med Chem"},{"issue":"6","key":"4119_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/cam4.144","volume":"2","author":"B Su","year":"2013","unstructured":"Su B, Gillard B, Gao L et al (2013) Src controls castration recurrence of CWR22 prostate cancer xenografts. Cancer Med 2(6):784\u2013792. https:\/\/doi.org\/10.1002\/cam4.144PMID: 24403252; PMCID: PMC3892383","journal-title":"Cancer Med"},{"key":"4119_CR33","doi-asserted-by":"crossref","unstructured":"Moore A, Yen, Moore S (2021) Topical Tirbanibulin eradication of periungual squamous cell carcinoma. JAAD Case Rep www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8283266\/","DOI":"10.1016\/j.jdcr.2021.06.013"},{"issue":"2","key":"4119_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S0304-419X(02)00040-9","volume":"1602","author":"C Margaret","year":"2002","unstructured":"Margaret C, Frame (2002) Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602(2):114\u2013130. https:\/\/doi.org\/10.1016\/S0304-419X(02)00040-9","journal-title":"Biochim Biophys Acta"},{"key":"4119_CR35","doi-asserted-by":"publisher","unstructured":"Heath MS, Bar A (2023) Basal Cell Carcinoma. Dermatol Clin. 41(1):13\u201321. https:\/\/doi.org\/10.1016\/j.det.2022.07.005. PMID: 36410973","DOI":"10.1016\/j.det.2022.07.005"},{"issue":"15","key":"4119_CR36","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.3390\/cancers15153927","volume":"15","author":"IJ Tan","year":"2023","unstructured":"Tan IJ, Pathak GN, Silver FH (2023) Topical treatments for basal cell carcinoma and actinic keratosis in the united States. Cancers (Basel) 15(15):3927. https:\/\/doi.org\/10.3390\/cancers15153927PMID: 37568743; PMCID: PMC10416997","journal-title":"Cancers (Basel)"},{"key":"4119_CR37","doi-asserted-by":"publisher","unstructured":"Tanese K (2019) Diagnosis and Management of Basal Cell Carcinoma. Curr Treat Options Oncol. 20(2):13. https:\/\/doi.org\/10.1007\/s11864-019-0610-0. PMID: 30741348","DOI":"10.1007\/s11864-019-0610-0"},{"key":"4119_CR38","doi-asserted-by":"publisher","unstructured":"Heppt MV, Dykukha I, Graziadio S et al (2022) Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe. J Clin Med. 11(6):1654. https:\/\/doi.org\/10.3390\/jcm11061654. PMID: 35329979","DOI":"10.3390\/jcm11061654"},{"key":"4119_CR39","unstructured":"Almirall SA (2021) A Multi-Center study to evaluate the efficacy and safety of KX2-391 ointment 1% on actinic keratosis on face or scalp (AK004). Clinicaltrials.Gov, 10 Mar. www.clinicaltrials.gov\/ct2\/show\/NCT03285490"},{"key":"4119_CR40","doi-asserted-by":"crossref","unstructured":"Bhatia N et al Safety and tolerability of Tirbanibulin ointment 1% treatment on 100 cm\u00b2 of the face or scalp in patients with actinic keratosis: A phase 3 study. JAAD Int, Elsevier, 18 July 2024, www.sciencedirect.com\/science\/article\/pii\/S2666328724000981","DOI":"10.1016\/j.jdin.2024.07.001"},{"key":"4119_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1743-422X-10-79","volume":"10","author":"A Szalm\u00e1s","year":"2013","unstructured":"Szalm\u00e1s A, Gy\u00f6ngy\u00f6si E, Ferenczi A et al (2013) Activation of Src, Fyn and yes non-receptor tyrosine kinases in keratinocytes expressing human papillomavirus (HPV) type 16 E7 oncoprotein. Virol J 10:79. https:\/\/doi.org\/10.1186\/1743-422X-10-79PMID: 23497302; PMCID: PMC3608944","journal-title":"Virol J"},{"issue":"14","key":"4119_CR42","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.3390\/jcm12144837","volume":"12","author":"MC Kirchberger","year":"2023","unstructured":"Kirchberger MC, Gfesser M, Erdmann M et al (2023) Tirbanibulin 1% ointment significantly reduces the actinic keratosis area and severity index in patients with actinic keratosis. J Clin Med 12(14):4837. https:\/\/doi.org\/10.3390\/jcm12144837PMID: 37510952; PMCID: PMC10381110","journal-title":"J Clin Med"},{"key":"4119_CR43","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/ijd.17168","volume":"63","author":"G Nazzaro","year":"2024","unstructured":"Nazzaro G, Carugno A, Bortoluzzi P, Buffon S et al (2024) Efficacy and tolerability of Tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients. Int J Dermatol 63:1566\u20131574","journal-title":"Int J Dermatol"},{"key":"4119_CR44","doi-asserted-by":"publisher","first-page":"adv15296","DOI":"10.2340\/actadv.v103.15296","volume":"103","author":"\u00c1 Iglesias-Puzas","year":"2023","unstructured":"Iglesias-Puzas \u00c1, Conde-Taboada A, Campos-Mu\u00f1oz L, Sirgado-Mart\u00ednez A, L\u00f3pez-Bran E (2023) 1% Tirbanibulin ointment for actinic keratoses on upper extremities: A retrospective case review study. Acta Derm Venereol 103:adv15296. https:\/\/doi.org\/10.2340\/actadv.v103.15296PMID: 37876333; PMCID: PMC10614645","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"4119_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/medicina60020225","volume":"60","author":"F Li Pomi","year":"2024","unstructured":"Li Pomi F, Vaccaro M, Pallio G, Rottura M, Irrera N, Borgia F (2024) Tirbanibulin 1% ointment for actinic keratosis: results from a Real-Life study. Med (Kaunas) 60(2):225. https:\/\/doi.org\/10.3390\/medicina60020225PMID: 38399512; PMCID: PMC10890708","journal-title":"Med (Kaunas)"},{"issue":"12","key":"4119_CR46","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/ph16121686","volume":"16","author":"E Campione","year":"2023","unstructured":"Campione E, Rivieccio A, Gaeta Shumak R et al (2023) Preliminary evidence of efficacy, safety, and treatment satisfaction with Tirbanibulin 1% ointment: A clinical perspective on actinic keratoses. Pharmaceuticals 16(12):1686. https:\/\/doi.org\/10.3390\/ph16121686","journal-title":"Pharmaceuticals"},{"issue":"3","key":"4119_CR47","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4143\/crt.2016.168","volume":"49","author":"S Kim","year":"2017","unstructured":"Kim S, Min A, Lee KH et al (2017) Antitumor effect of KX-01 through inhibiting Src family kinases and mitosis. Cancer Res Treat 49(3):643\u2013655. https:\/\/doi.org\/10.4143\/crt.2016.168PMID: 27737538; PMCID: PMC5512373","journal-title":"Cancer Res Treat"},{"key":"4119_CR48","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/ijd.14767","volume":"59","author":"C Dianzani","year":"2020","unstructured":"Dianzani C, Conforti C, Giuffrida R et al (2020) Current therapies for actinic keratosis. Int J Dermatol 59:677\u2013684","journal-title":"Int J Dermatol"},{"key":"4119_CR49","doi-asserted-by":"publisher","unstructured":"Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR (2021) Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 384(6):512\u2013520. https:\/\/doi.org\/10.1056\/NEJMoa2024040. PMID: 33567191","DOI":"10.1056\/NEJMoa2024040"},{"key":"4119_CR50","unstructured":"Almirall SA (2021) A Multi-Center study to evaluate the efficacy and safety of KX2-391 ointment 1% on AK on face or scalp (AK003). Clinicaltrials.Gov, 13 Apr. clinicaltrials.gov\/study\/NCT03285477"},{"key":"4119_CR51","doi-asserted-by":"publisher","unstructured":"Schlesinger T, Kircik L, Lebwohl M, Patel VA, Berman B, Bhatia N, Rigel D, Armstrong A, Rosso JD, Narayanan S, Koscielny V, Kasujee I (2024) Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK). J Drugs Dermatol. 23(5):338\u2013346. https:\/\/doi.org\/10.36849\/JDD.8264. PMID: 38709702","DOI":"10.36849\/JDD.8264"},{"issue":"6","key":"4119_CR52","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s13555-024-01178-0","volume":"14","author":"F Li Pomi","year":"2024","unstructured":"Li Pomi F, Peterle L, d\u2019Aloja A, Di Tano A, Vaccaro M, Borgia F (2024) Anti-aging effects of Tirbanibulin 1% ointment: A Real-Life experience. Dermatol Ther (Heidelb) 14(6):1683\u20131696. https:\/\/doi.org\/10.1007\/s13555-024-01178-0Epub 2024 May 14. PMID: 38740726; PMCID: PMC11169325","journal-title":"Dermatol Ther (Heidelb)"},{"key":"4119_CR53","doi-asserted-by":"publisher","unstructured":"Kadono S, Manaka I, Kawashima M, Kobayashi T, Imokawa G (2001) The role of the epidermal endothelin cascade in the hyperpigmentation mechanism of lentigo senilis. J Invest Dermatol. 116(4):571-7. https:\/\/doi.org\/10.1046\/j.1523-1747.2001.01296.x. PMID: 11286625","DOI":"10.1046\/j.1523-1747.2001.01296.x"},{"key":"4119_CR54","doi-asserted-by":"publisher","unstructured":"Goorochurn R, Viennet C, Granger C, Fanian F, Varin-Blank N, Roy CL, Humbert P (2016) Biological processes in solar lentigo: insights brought by experimental models. Exp Dermatol. 25(3):174-7. https:\/\/doi.org\/10.1111\/exd.12937. PMID: 26739821","DOI":"10.1111\/exd.12937"},{"issue":"15","key":"4119_CR55","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.3390\/ijms20153666","volume":"20","author":"G Imokawa","year":"2019","unstructured":"Imokawa G (2019) Melanocyte activation mechanisms and rational therapeutic treatments of solar Lentigos. Int J Mol Sci 20(15):3666. https:\/\/doi.org\/10.3390\/ijms20153666PMID: 31357457; PMCID: PMC6695993","journal-title":"Int J Mol Sci"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04119-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:00:16Z","timestamp":1742385616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04119-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4119"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04119-9","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve any identifying patient information, images, or sensitive data. Therefore, no patient consent was required. The research adheres to the ethical standards outlined by the ICMJE Recommendations regarding patient privacy and confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"603"}}